Cancer Med

Common medications tied to higher adverse event rates in breast cancer patients

November 14, 2025

A pooled analysis of 19 clinical trials (N = 23,211) found that proton pump inhibitor (PPI) use was associated with poorer overall and progression-free survival, and increased risk of grade ≥3 adverse events in breast cancer patients. Beta-blockers, ACE inhibitors/ARBs, and calcium channel blockers were associated with higher adverse event rates but didn't affect survival. Statins and metformin showed no significant associations with survival or adverse events.

Clinical takeaway: Concomitant medication use may influence outcomes in breast cancer care, warranting further investigation.

Source:

Modi ND, et al. (2025, November). Cancer Med. Associations of Commonly Used Concomitant Medications With Survival and Adverse Event Outcomes in Breast Cancer. https://pubmed.ncbi.nlm.nih.gov/41163361/